RJT
CORT icon

Raymond James Trust’s Corcept Therapeutics CORT Stock Holding History

Raymond James Trust’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$833K Hold
18,000
– – 0.02% 561
2024
Q2 		$585K Hold
18,000
– – 0.01% 656
2024
Q1 		$453K Hold
18,000
– – 0.01% 762
2023
Q4 		$585K Hold
18,000
– – 0.02% 623
2023
Q3 		$490K Hold
18,000
– – 0.01% 646
2023
Q2 		$401K Hold
18,000
– – 0.01% 753
2023
Q1 		$390K Hold
18,000
– – 0.01% 742
2022
Q4 		$366K Buy
+18,000
New +$451K 0.01% 743

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Raymond James Trust's CORT Position: Q3 2024 in Review

Raymond James Trust held its Corcept Therapeutics (CORT) position steady in Q3 2024 at 18,000 shares worth $833K. The position accounts for 0.02% of the portfolio, ranked #561.

Raymond James Trust first reported a position in CORT in Q4 2022 and has held it in 8 quarters since. 321 funds tracked by Wall St. Rank hold CORT as of Q3 2024.

  • Raymond James Trust held 18,000 shares of Corcept Therapeutics worth $833K as of Q3 2024.
  • Raymond James Trust left its Corcept Therapeutics share count unchanged in Q3 2024.
  • Corcept Therapeutics made up 0.02% of Raymond James Trust's portfolio in Q3 2024, its #561 holding.
  • Raymond James Trust first reported a position in Corcept Therapeutics in Q4 2022 and has held it in 8 quarters since.
  • 321 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2024.

Based on Raymond James Trust's 13F filing for Q3 2024, filed 12 Nov 2024.